Galmed shareholders approve all AGM proposals

Galmed Pharmaceuticals’ shareholders approved all proposals at the September 3, 2026 annual meeting, with the results tied into existing S-8 and F-3 registration statements.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. (GLMD) reports that it held its Annual General Meeting of Shareholders on September 3, 2026. Shareholders approved all proposals presented at the meeting with the requisite majority under the Israeli Companies Law, 5759-1999. The report is also incorporated by reference into Galmed’s effective Form S-8 and Form F-3 registration statements.

Key Figures

Date of Annual General Meeting: September 3, 2026 Number of Form S-8 registration statements referenced: 4 Number of Form F-3 registration statements referenced: 2

3 metrics

Date of Annual General Meeting September 3, 2026 Date Galmed Pharmaceuticals held its Annual General Meeting of Shareholders

Number of Form S-8 registration statements referenced 4 Form S-8 Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399

Number of Form F-3 registration statements referenced 2 Form F-3 Registration Nos. 333-272722 and 333-283241

Key Terms

Annual General Meeting of Shareholders, proxy statement, Registration Statement on Form F-3, incorporated by reference

4 terms

Annual General Meeting of Shareholders regulatory

"On September 3, 2026, Galmed Pharmaceuticals Ltd. held an Annual General Meeting of Shareholders"

proxy statement regulatory

"shareholders voted on all of the proposals described in the proxy statement for the Meeting"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Registration Statement on Form F-3 regulatory

"and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241)"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

incorporated by reference regulatory

"This Form 6-K is incorporated by reference into the Company’s Registration Statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed Pharmaceuticals (GLMD) announce in the September 2026 Form 6-K?

Galmed Pharmaceuticals announced that on September 3, 2026 it held its Annual General Meeting of Shareholders and that shareholders approved all proposals presented, in accordance with the Israeli Companies Law, 5759-1999.

Were all proposals approved at Galmed Pharmaceuticals’ September 3, 2026 shareholder meeting?

Yes. Galmed Pharmaceuticals states that the proposals brought before shareholders at the September 3, 2026 Annual General Meeting were approved by the requisite majority under the Israeli Companies Law, 5759-1999.

How does this Galmed Pharmaceuticals (GLMD) 6-K affect its registration statements?

The report states it is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and on Form F-3 (Nos. 333-272722, 333-283241).

Which proxy materials were used for Galmed Pharmaceuticals’ September 3, 2026 meeting?

Shareholders voted on proposals described in the proxy statement furnished on Form 6-K on July 22, 2026, as amended by an Amended Proxy Statement furnished on Form 6-K on August 19, 2026.

Under which law were Galmed Pharmaceuticals’ shareholder approvals assessed?

The company states that the proposals were approved by shareholders with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:07 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:05 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 3, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) held an Annual General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on all of the proposals described in the proxy statement for the Meeting included as an exhibit to the Company’s Report of Foreign Private Issuer on Form 6-K furnished by the Company to the Securities and Exchange Commission (the “SEC”) on July 22, 2026, as amended by the Amended Proxy Statement which was included as an exhibit to the Company’s report of Foreign Private Issuer on Form 6-K, furnished to the SEC on August 19, 2026. The proposals brought before the shareholders at the Meeting were approved by the shareholders of the Company with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: September 3, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer